ARGATROBAN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ARGATROBAN (ARGATROBAN).

How it works

Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, XIII, and platelet aggregation.

What the body does with it

Metabolism	Hepatic metabolism primarily via hydroxylation and oxidation; minimally metabolized by CYP450 enzymes. Excreted in feces via biliary secretion.
Excretion	Primarily hepatic (CYP450) metabolism; fecal (~65% as unchanged and metabolites) and renal (~22% with ~16% unchanged) elimination.
Half-life	Terminal half-life 39-51 minutes (dose-dependent); clinical context: continuous IV infusion required for stable anticoagulation.
Protein binding	~54% bound to human serum albumin and α1-acid glycoprotein.
Volume of Distribution	0.174 L/kg; primarily confined to extracellular fluid.
Bioavailability	IV: 100% (by definition); not orally administered.
Onset of Action	IV: immediate (within minutes); rapid anticoagulation.
Duration of Action	IV infusion: anticoagulation ceases within 2-4 hours after discontinuation; monitored via aPTT.

Classification & Brands

Dosing & administration

Initial dose: 2 mcg/kg/min IV continuous infusion; adjust to maintain aPTT 1.5-3 times baseline. For patients with HIT undergoing PCI: initial bolus 350 mcg/kg IV, then 25 mcg/kg/min IV infusion.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for renal impairment. Not significantly cleared renally.
Liver impairment	For Child-Pugh class A: initial dose 1.25 mcg/kg/min IV; for Child-Pugh class B: 0.625 mcg/kg/min IV; for Child-Pugh class C: contraindicated or use with extreme caution, initial dose 0.3125 mcg/kg/min IV. Titrate carefully to aPTT.
Pediatric use	Safety and efficacy not established in children; limited data: initial dose 0.75 mcg/kg/min IV continuous infusion, titrate to aPTT 1.5-3 times baseline.
Geriatric use	No specific dose adjustment, but may have increased risk of bleeding; start at lower end of dosing range (e.g., 1.5 mcg/kg/min) and titrate carefully.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ARGATROBAN (ARGATROBAN).

Breastfeeding	Not known if excreted in human milk. M/P ratio unknown. Caution advised due to anticoagulant effects; consider discontinuing breastfeeding or drug based on importance.
Teratogenic Risk	Insufficient human data; animal studies show no teratogenic effects at doses up to 0.5 mg/kg/day IV. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Risk of bleeding, including intracranial and retroperitoneal hemorrhage. Do not use in patients with active major bleeding. Monitor coagulation parameters closely.

Side Effect Profile

Serious Effects

Absolute Contraindications

Active major bleeding, history of hypersensitivity to argatroban, severe hepatic impairment (Child-Pugh score >6), or inability to monitor coagulation parameters.

Clinical Precautions

Precautions	Risk of bleeding, especially in patients with renal impairment, hepatic impairment, or undergoing invasive procedures. May cause hyperglycemia in critically ill patients. Monitor aPTT and adjust dose accordingly. Use cautiously in patients with severe hypertension, recent surgery, or spinal/epidural puncture.
Food/Dietary	No known food interactions. Avoid excessive alcohol consumption as it may increase bleeding risk.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

ARGATROBAN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ARGATROBAN (ARGATROBAN).

How it works

Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, XIII, and platelet aggregation.

What the body does with it

Metabolism	Hepatic metabolism primarily via hydroxylation and oxidation; minimally metabolized by CYP450 enzymes. Excreted in feces via biliary secretion.
Excretion	Primarily hepatic (CYP450) metabolism; fecal (~65% as unchanged and metabolites) and renal (~22% with ~16% unchanged) elimination.
Half-life	Terminal half-life 39-51 minutes (dose-dependent); clinical context: continuous IV infusion required for stable anticoagulation.
Protein binding	~54% bound to human serum albumin and α1-acid glycoprotein.
Volume of Distribution	0.174 L/kg; primarily confined to extracellular fluid.
Bioavailability	IV: 100% (by definition); not orally administered.
Onset of Action	IV: immediate (within minutes); rapid anticoagulation.
Duration of Action	IV infusion: anticoagulation ceases within 2-4 hours after discontinuation; monitored via aPTT.

Classification & Brands

Dosing & administration

Initial dose: 2 mcg/kg/min IV continuous infusion; adjust to maintain aPTT 1.5-3 times baseline. For patients with HIT undergoing PCI: initial bolus 350 mcg/kg IV, then 25 mcg/kg/min IV infusion.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for renal impairment. Not significantly cleared renally.
Liver impairment	For Child-Pugh class A: initial dose 1.25 mcg/kg/min IV; for Child-Pugh class B: 0.625 mcg/kg/min IV; for Child-Pugh class C: contraindicated or use with extreme caution, initial dose 0.3125 mcg/kg/min IV. Titrate carefully to aPTT.
Pediatric use	Safety and efficacy not established in children; limited data: initial dose 0.75 mcg/kg/min IV continuous infusion, titrate to aPTT 1.5-3 times baseline.
Geriatric use	No specific dose adjustment, but may have increased risk of bleeding; start at lower end of dosing range (e.g., 1.5 mcg/kg/min) and titrate carefully.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ARGATROBAN (ARGATROBAN).

Breastfeeding	Not known if excreted in human milk. M/P ratio unknown. Caution advised due to anticoagulant effects; consider discontinuing breastfeeding or drug based on importance.
Teratogenic Risk	Insufficient human data; animal studies show no teratogenic effects at doses up to 0.5 mg/kg/day IV. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Risk of bleeding, including intracranial and retroperitoneal hemorrhage. Do not use in patients with active major bleeding. Monitor coagulation parameters closely.

Side Effect Profile

Serious Effects

Absolute Contraindications

Active major bleeding, history of hypersensitivity to argatroban, severe hepatic impairment (Child-Pugh score >6), or inability to monitor coagulation parameters.

Clinical Precautions

Precautions	Risk of bleeding, especially in patients with renal impairment, hepatic impairment, or undergoing invasive procedures. May cause hyperglycemia in critically ill patients. Monitor aPTT and adjust dose accordingly. Use cautiously in patients with severe hypertension, recent surgery, or spinal/epidural puncture.
Food/Dietary	No known food interactions. Avoid excessive alcohol consumption as it may increase bleeding risk.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

Clinical Pearls	Argatroban is a direct thrombin inhibitor used for heparin-induced thrombocytopenia (HIT). Monitor aPTT closely; target 1.5–3 times baseline. No reversal agent; half-life ~50 min. Use with caution in hepatic impairment. Do not use if history of intracranial hemorrhage.
Patient Advice	Report any unusual bleeding or bruising immediately. · Avoid aspirin, NSAIDs, and other blood thinners unless prescribed. · Inform all healthcare providers you are taking argatroban. · Seek medical attention for signs of allergic reaction (rash, hives, difficulty breathing).